{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:24:25Z","timestamp":1787181865807,"version":"build-2736575974"},"reference-count":183,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013228","name":"Quebec Network for Research on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013228","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000196","name":"Fondation canadienne pour l'innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Quebec Health Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012651","name":"Montreal Heart Institute Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012651","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.biopha.2026.119824","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:19:59Z","timestamp":1785493199000},"page":"119824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Translational consistency of gene therapy strategies targeting inflammation in atrial fibrillation\u2019s management"],"prefix":"10.1016","volume":"202","author":[{"given":"Ma\u00efssa","family":"Zemmouchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aseel","family":"El-Fermawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anya","family":"Benagdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Baaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4291-8314","authenticated-orcid":false,"given":"Roddy","family":"Hiram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119824_bib1","doi-asserted-by":"crossref","DOI":"10.15420\/aer.2025.33","article-title":"The Global Impact of Atrial Fibrillation","volume":"14","author":"Karatela","year":"2025","journal-title":"Arrhythm. Electrophysiol. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2026.119824_bib2","first-page":"467","article-title":"Atrial Fibrillation Associated with Heart Failure, Stroke and Mortality","volume":"5","author":"Bordignon","year":"2012","journal-title":"J. Atr. Fibrillation"},{"issue":"24","key":"10.1016\/j.biopha.2026.119824_bib3","doi-asserted-by":"crossref","first-page":"7846","DOI":"10.3390\/jcm13247846","article-title":"Advances in Atrial Fibrillation Management: A Guide for General Internists","volume":"13","author":"Pham","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.biopha.2026.119824_bib4","first-page":"318","article-title":"Die 2024 ESC-Leitlinien zum Management von Vorhofflimmern: AF-CARE als neues Credo [The 2024 ESC guidelines for management of atrial fibrillation: AF-CARE as new credo]","volume":"35","author":"Wolfes","year":"2024"},{"issue":"6","key":"10.1016\/j.biopha.2026.119824_bib5","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s12265-025-10685-0","article-title":"Gene Therapies in Atrial Fibrillation","volume":"18","author":"O'Donnell","year":"2025","journal-title":"J. Cardiovasc. Transl. Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119824_bib6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1186\/s12872-024-03983-z","article-title":"Antiarrhythmic drug therapy and catheter ablation in patients with paroxysmal or persistent atrial fibrillation: a systematic review and meta-analysis","volume":"24","author":"Chander","year":"2024","journal-title":"BMC Cardiovasc. Disord."},{"issue":"2","key":"10.1016\/j.biopha.2026.119824_bib7","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/j.2040-4603.2015.tb00626.x","article-title":"Atrial fibrillation: mechanisms, therapeutics, and future directions","volume":"5","author":"Pellman","year":"2015","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.biopha.2026.119824_bib8","article-title":"Cardiac cytokine therapy? Relevance of targeting inflammatory mediators to combat cardiac arrhythmogenic remodeling","volume":"37","author":"Hiram","year":"2021","journal-title":"Int. J. Cardiol. Heart Vasc."},{"issue":"10","key":"10.1016\/j.biopha.2026.119824_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2017.e00406","article-title":"Inflammatory activation of human cardiac fibroblasts leads to altered calcium signaling, decreased connexin 43 expression and increased glutamate secretion","volume":"3","author":"Ski\u00f6ldebrand","year":"2017","journal-title":"Heliyon"},{"issue":"2","key":"10.1016\/j.biopha.2026.119824_bib10","first-page":"839","article-title":"Connexin Remodeling Contributes to Atrial Fibrillation","volume":"6","author":"Jennings","year":"2013","journal-title":"J. Atr. Fibrillation"},{"issue":"6","key":"10.1016\/j.biopha.2026.119824_bib11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrcardio.2013.53","article-title":"Genetic mechanisms of atrial fibrillation: impact on response to treatment","volume":"10","author":"Darbar","year":"2013","journal-title":"Nat. Rev. Cardiol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119824_bib12","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2025.2516697","article-title":"S. Unlocking the potential: advancements and applications of gene therapy in severe disorders","volume":"57","author":"Ingle","year":"2025","journal-title":"Ann. Med."},{"issue":"11","key":"10.1016\/j.biopha.2026.119824_bib13","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1089\/hum.2017.172","article-title":"Small But Increasingly Mighty: Latest Advances in AAV Vector Research, Design, and Evolution","volume":"28","author":"Grimm","year":"2017","journal-title":"Hum. Gene Ther."},{"issue":"24","key":"10.1016\/j.biopha.2026.119824_bib14","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1021\/acs.biochem.5c00480","article-title":"CRISPR Technology: Transforming the Future of Medicine and Diagnostics","volume":"64","author":"Iyer","year":"2025","journal-title":"Biochemistry"},{"key":"10.1016\/j.biopha.2026.119824_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2026.1705565","article-title":"The mechanism of electrical remodeling in atrial fibrillation and current research status of natural drugs and active ingredients inhibiting atrial electrical remodeling","volume":"13","author":"Huang","year":"2026","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.biopha.2026.119824_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108053","article-title":"Targeting the NLRP3 inflammasome in cardiovascular diseases","volume":"236","author":"Toldo","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2026.119824_bib17","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.2147\/JIR.S370483","article-title":"The NLRP3 Inflammasome as a Novel Therapeutic Target for Cardiac Fibrosis","volume":"15","author":"Fan","year":"2022","journal-title":"J. Inflamm. Res."},{"issue":"3","key":"10.1016\/j.biopha.2026.119824_bib18","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3390\/medsci13030102","article-title":"Gene Therapy for Cardiac Arrhythmias: Mechanisms, Modalities and Therapeutic Applications","volume":"13","author":"Karakasis","year":"2025","journal-title":"Med. Sci. (Basel)"},{"key":"10.1016\/j.biopha.2026.119824_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121564","article-title":"Inhibition of transglutaminase 2 (TG2) ameliorates ventricular fibrosis in isoproterenol-induced heart failure in rats","volume":"321","author":"Al-U'datt","year":"2023","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.biopha.2026.119824_bib20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/cvr\/cvp148","article-title":"Targeted G-protein inhibition as a novel approach to decrease vagal atrial fibrillation by selective parasympathetic attenuation","volume":"83","author":"Aistrup","year":"2009","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119824_bib21","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1161\/CIRCRESAHA.115.307878","article-title":"Constitutive Expression of a Dominant-Negative TGF-\u03b2 Type II Receptor in the Posterior Left Atrium Leads to Beneficial Remodeling of Atrial Fibrillation Substrate","volume":"119","author":"Kunamalla","year":"2016","journal-title":"Circ. Res."},{"issue":"2","key":"10.1016\/j.biopha.2026.119824_bib22","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1161\/CIRCULATIONAHA.111.053272","article-title":"Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation","volume":"125","author":"Igarashi","year":"2012","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.biopha.2026.119824_bib23","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/cvr\/cvr209","article-title":"Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model","volume":"92","author":"Bikou","year":"2011","journal-title":"Cardiovasc. Res."},{"issue":"2","key":"10.1016\/j.biopha.2026.119824_bib24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.hrthm.2011.09.008","article-title":"Genetic suppression of atrial fibrillation using a dominant-negative ether-a-go-go-related gene mutant","volume":"9","author":"Soucek","year":"2012","journal-title":"Heart Rhythm."},{"issue":"2","key":"10.1016\/j.biopha.2026.119824_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70091","article-title":"Gene therapy for genetic diseases: challenges and future directions","volume":"6","author":"Qie","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.biopha.2026.119824_bib26","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijcard.2019.07.057","article-title":"Gene therapy for atrial fibrillation - How close to clinical implementation?","volume":"296","author":"Trivedi","year":"2019","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119824_bib27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41569-025-01168-5","article-title":"Gene therapy for cardiac arrhythmias","volume":"23","author":"Bains","year":"2026","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.biopha.2026.119824_bib28","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.yjmcc.2024.09.004","article-title":"Gene therapy for atrial fibrillation","volume":"196","author":"Mo","year":"2024","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"36","key":"10.1016\/j.biopha.2026.119824_bib29","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur. Heart J."},{"issue":"11","key":"10.1016\/j.biopha.2026.119824_bib30","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1161\/CIRCULATIONAHA.123.066989","article-title":"Antiarrhythmic Drug Therapy: Where Do We Go From Here?","volume":"149","author":"Kowey","year":"2024","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.biopha.2026.119824_bib31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00399-021-00836-6","article-title":"Late arrhythmia recurrence after atrial fibrillation ablation: incidence, mechanisms and clinical implications","volume":"33","author":"Erhard","year":"2022","journal-title":"Herzschrittmacher Elektro"},{"issue":"9","key":"10.1016\/j.biopha.2026.119824_bib32","article-title":"Comparison of Clinical Factors Between Recurrent and Non-recurrent Atrial Fibrillation Within One Year After Catheter Ablation by the Same Operators at a Regional Core Hospital in Japan","volume":"17","author":"Katagiri","year":"2025","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.biopha.2026.119824_bib33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/cells15010036","article-title":"Molecular Mechanisms of Atrial Fibrillation Recurrence After Successful Catheter Ablation","volume":"15","author":"Sanusi","year":"2025","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.biopha.2026.119824_bib34","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3390\/biom16020216","article-title":"Pro- and Anti-Inflammatory Cytokines' Implication in Right Heart Disease, Arrhythmogenesis, and Atrial Fibrillation","volume":"16","author":"Khider","year":"2026","journal-title":"Biomolecules"},{"issue":"7","key":"10.1016\/j.biopha.2026.119824_bib35","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1503\/cmaj.1031277","article-title":"Canadian Registry of Atrial Fibrillation investigators. Limitations to antiarrhythmic drug use in patients with atrial fibrillation","volume":"171","author":"Humphries","year":"2004","journal-title":"CMAJ"},{"issue":"1","key":"10.1016\/j.biopha.2026.119824_bib36","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1080\/07853890.2021.1930137","article-title":"Rate control strategies for atrial fibrillation","volume":"53","author":"Alobaida","year":"2021","journal-title":"Ann. Med."},{"issue":"2","key":"10.1016\/j.biopha.2026.119824_bib37","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/FJC.0000000000001707","article-title":"Gene- and cell-based therapy in cardiovascular diseases","volume":"86","author":"Zhang","year":"2025","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119824_bib38","doi-asserted-by":"crossref","first-page":"56","DOI":"10.17691\/stm2025.17.6.06","article-title":"Gene Therapy Techniques and Delivery Methods (Review)","volume":"17","author":"Shchukina","year":"2025","journal-title":"Sovrem. Tekhnologii Med."},{"issue":"12","key":"10.1016\/j.biopha.2026.119824_bib39","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euae298","article-title":"Spotlight on the 2024 ESC\/EACTS management of atrial fibrillation guidelines: 10 novel key aspects","volume":"26","author":"Rienstra","year":"2024","journal-title":"Europace"},{"issue":"3","key":"10.1016\/j.biopha.2026.119824_bib40","doi-asserted-by":"crossref","first-page":"139","DOI":"10.15420\/aer.2014.3.3.139","article-title":"The Use of Gene Therapy for Ablation of Atrial Fibrillation","volume":"3","author":"Liu","year":"2014","journal-title":"Arrhythm. Electrophysiol. Rev."},{"issue":"5","key":"10.1016\/j.biopha.2026.119824_bib41","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.yjmcc.2010.07.022","article-title":"Gene therapy strategies for cardiac electrical dysfunction","volume":"50","author":"Greener","year":"2011","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.biopha.2026.119824_bib42","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pharmthera.2017.06.005","article-title":"Current state of the art for cardiac arrhythmia gene therapy","volume":"176","author":"Donahue","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2026.119824_bib43","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/eurheartj\/ehr269","article-title":"Suppression of Persistent Atrial Fibrillation by Genetic Knockdown of Caspase 3: A Pre-Clinical Pilot Study","volume":"34","author":"Trappe","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2026.119824_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008681","article-title":"Biological Pacemaker Created by Minimally Invasive Somatic Reprogramming in Pigs with Complete Heart Block","volume":"6","author":"Hu","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biopha.2026.119824_bib45","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1161\/CIRCULATIONAHA.108.809301","article-title":"Epicardial Border Zone Overexpression of Skeletal Muscle Sodium Channel SkM1 Normalizes Activation, Preserves Conduction, and Suppresses Ventricular Arrhythmia: An In Silico, In Vivo, In Vitro Study","volume":"119","author":"Lau","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2026.119824_bib46","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ymthe.2022.11.017","article-title":"Direct Intramyocardial Injection of VEGF MRNA in Patients Undergoing Coronary Artery Bypass Grafting","volume":"31","author":"Anttila","year":"2023","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.biopha.2026.119824_bib47","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1111\/jce.15116","article-title":"Recent advances in gene therapy for atrial fibrillation","volume":"32","author":"Yoo","year":"2021","journal-title":"J. Cardiovasc. Electrophysiol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119824_bib48","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12951-024-02485-6","article-title":"Engineered nanoparticles promote cardiac tropism of AAV vectors","volume":"22","author":"Switala","year":"2024","journal-title":"J. Nanobiotechnology"},{"issue":"3","key":"10.1016\/j.biopha.2026.119824_bib49","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcab030","article-title":"Ligand-mediated delivery of RNAi-based therapeutics for the treatment of oncological diseases","volume":"3","author":"Abdelaal","year":"2021","journal-title":"NAR Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2026.119824_bib50","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ymthe.2024.01.028","article-title":"Current RNA strategies in treating cardiovascular diseases","volume":"32","author":"Chia","year":"2024","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2026.119824_bib51","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.hrthm.2024.02.001","article-title":"Adeno-associated virus-mediated gene therapy for cardiac tachyarrhythmia: A systematic review and meta-analysis","volume":"21","author":"Mundisugih","year":"2024","journal-title":"Heart Rhythm."},{"key":"10.1016\/j.biopha.2026.119824_bib52","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijcard.2018.10.020","article-title":"Role of inflammatory signaling in atrial fibrillation","volume":"287","author":"Scott","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.biopha.2026.119824_bib53","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.2147\/IJN.S430877","article-title":"Advancements in Macrophage-Targeted Drug Delivery for Effective Disease Management","volume":"18","author":"Liu","year":"2023","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2026.119824_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1467089","article-title":"Cardiac macrophages in maintaining heart homeostasis and regulating ventricular remodeling of heart diseases","volume":"15","author":"Kang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119824_bib55","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.addr.2020.06.002","article-title":"Lipid nanoparticles for nucleic acid delivery: Current perspectives","volume":"154-155","author":"Samaridou","year":"2020","journal-title":"Adv. Drug. Deliv. Rev."},{"issue":"17-18","key":"10.1016\/j.biopha.2026.119824_bib56","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1089\/hum.2024.106","article-title":"Lipid Nanoparticles for Nucleic Acid Delivery Beyond the Liver","volume":"35","author":"Saber","year":"2024","journal-title":"Hum. Gene Ther."},{"issue":"12","key":"10.1016\/j.biopha.2026.119824_bib57","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3390\/pharmaceutics16121521","article-title":"Effect of Lipid Nanoparticle Physico-Chemical Properties and Composition on Their Interaction with the Immune System","volume":"16","author":"Catenacci","year":"2024","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.biopha.2026.119824_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109804","article-title":"Optimized lipid nanoparticles (LNPs) for organ-selective nucleic acids delivery in vivo","volume":"27","author":"Zhang","year":"2024","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.biopha.2026.119824_bib59","article-title":"The evolution of lipid nanoparticles: Paving the way for next-generation nucleic acid medicines","volume":"21","author":"Lin","year":"2026","journal-title":"Asian J. Pharm. Sci."},{"issue":"10","key":"10.1016\/j.biopha.2026.119824_bib60","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1016\/j.ymthe.2024.09.002","article-title":"The best of both worlds: AAV-mediated gene transfer empowered by LNP delivery of Sleeping Beauty transposase for durable transgene expression in vivo","volume":"32","author":"Sandoval-Villegas","year":"2024","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.biopha.2026.119824_bib61","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3390\/jcdd12100401","article-title":"Extensive Approach to Atrial Fibrillation: Background and Future Perspectives","volume":"12","author":"Xhakupi","year":"2025","journal-title":"J. Cardiovasc. Dev. Dis."},{"issue":"2","key":"10.1016\/j.biopha.2026.119824_bib62","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10557-023-07491-8","article-title":"Long Non-coding RNA Involved in the Pathophysiology of Atrial Fibrillation","volume":"39","author":"Zhong","year":"2025","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119824_bib63","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev-genet-011725-094039","article-title":"Gene Editing Applications as Future Cardiovascular Therapies","volume":"59","author":"Tadokoro","year":"2025","journal-title":"Annu. Rev. Genet."},{"issue":"4","key":"10.1016\/j.biopha.2026.119824_bib64","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3390\/cells14040277","article-title":"Prime Editing: Mechanistic Insights and DNA Repair Modulation","volume":"14","author":"Mentani","year":"2025","journal-title":"Cells"},{"issue":"26","key":"10.1016\/j.biopha.2026.119824_bib65","first-page":"05560","article-title":"Gene Editing Therapy in Cardiovascular Disease: 2026 ACC Scientific Statement","volume":"S0735-1097","author":"Ambardekar","year":"2026","journal-title":"A Report. Am. Coll. Cardiol. J. Am. Coll. Cardiol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119824_bib66","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.71159","article-title":"Advances in CRISPR Base Editing: From Molecular Evolution to Therapeutic Applications in Genomic Medicine","volume":"30","author":"Aliciaslan","year":"2026","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119824_bib67","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ymthe.2025.08.047","article-title":"Epigenome editing based treatment: Progresses and challenges","volume":"34","author":"Yuan","year":"2026","journal-title":"Mol. Ther."},{"issue":"12","key":"10.1016\/j.biopha.2026.119824_bib68","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1093\/cvr\/cvaf109","article-title":"Gene therapy in cardiac and vascular diseases: a review of approaches to treat genetic and common cardiovascular diseases with novel gene-based therapeutics","volume":"121","author":"Musolino","year":"2025","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119824_bib69","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1146\/annurev-pharmtox-062124-025403","article-title":"Metabolic and Inflammatory Mechanisms Driving Atrial Fibrillation","volume":"66","author":"Stoll","year":"2026","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119824_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102733","article-title":"Precision gene editing: The power of CRISPR-Cas in modern genetics","volume":"36","author":"Joo","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"36","key":"10.1016\/j.biopha.2026.119824_bib71","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1021\/acs.biochem.9b00573","article-title":"Off-Target Editing by CRISPR-Guided DNA Base Editors","volume":"58","author":"Park","year":"2019","journal-title":"Biochemistry"},{"issue":"5","key":"10.1016\/j.biopha.2026.119824_bib72","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/HCO.0000000000000985","article-title":"The potential of CRISPR-Cas9 prime editing for cardiovascular disease research and therapy","volume":"37","author":"Bharucha","year":"2022","journal-title":"Curr. Opin. Cardiol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119824_bib73","doi-asserted-by":"crossref","first-page":"5253","DOI":"10.3390\/ijms26115253","article-title":"Epigenetic Drivers of Atrial Fibrillation: Mechanisms, Biomarkers, and Therapeutic Targets","volume":"26","author":"Karakasis","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119824_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108720","article-title":"Gene editing in common cardiovascular diseases","volume":"263","author":"Lauerer","year":"2024","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2026.119824_bib75","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1046\/j.1365-2567.2001.01256.x","article-title":"The use of human CD68 transcriptional regulatory sequences to direct high-level expression of class A scavenger receptor in macrophages in vitro and in vivo","volume":"103","author":"Gough","year":"2001","journal-title":"Immunology"},{"issue":"11","key":"10.1016\/j.biopha.2026.119824_bib76","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.3390\/pathogens12111301","article-title":"Transcriptional Targeting Approaches in Cardiac Gene Transfer Using AAV Vectors","volume":"12","author":"Schr\u00f6der","year":"2023","journal-title":"Pathogens"},{"issue":"2","key":"10.1016\/j.biopha.2026.119824_bib77","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3390\/v17020239","article-title":"Adeno-Associated Virus Vectors: Principles, Practices, and Prospects in Gene Therapy","volume":"17","author":"Zwi-Dantsis","year":"2025","journal-title":"Viruses"},{"issue":"11","key":"10.1016\/j.biopha.2026.119824_bib78","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1016\/j.ymthe.2023.09.012","article-title":"Optimal delivery of RNA interference by viral vectors for cancer therapy","volume":"31","author":"Wong","year":"2023","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.biopha.2026.119824_bib79","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3349\/ymj.2024.0127","article-title":"Gene Therapy for Cardiovascular Disease: Clinical Perspectives","volume":"65","author":"Lee","year":"2024","journal-title":"Yonsei Med. J."},{"issue":"11","key":"10.1016\/j.biopha.2026.119824_bib80","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.3390\/pharmaceutics17111492","article-title":"Emerging Technologies Tackling Adeno-Associated Viruses (AAV) Immunogenicity in Gene Therapy Applications","volume":"17","author":"Egorova","year":"2025","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.biopha.2026.119824_bib81","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2023.01.010","article-title":"Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy","volume":"31","author":"Schulz","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2026.119824_bib82","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.omtm.2022.02.011","article-title":"Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations","volume":"25","author":"Mendell","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"2","key":"10.1016\/j.biopha.2026.119824_bib83","article-title":"Non-clinical safety considerations on genome editing using the CRISPR\/Cas system","volume":"13","author":"Toofan","year":"2025","journal-title":"Genes. Dis."},{"issue":"4","key":"10.1016\/j.biopha.2026.119824_bib84","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.ymthe.2024.02.002","article-title":"High-dose systemic adeno-associated virus vector administration causes liver and sinusoidal endothelial cell injury","volume":"32","author":"Hordeaux","year":"2024","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2026.119824_bib85","first-page":"982","article-title":"Emerging Gene Therapies for Inherited Arrhythmia Syndromes","volume":"42","author":"Grisorio","year":"2026","journal-title":"Can. J. Cardiol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119824_bib86","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.125.013361","article-title":"Gene Therapy for Cardiomyopathy: Tools, Targets, and Trials","volume":"19","author":"Agarwal","year":"2026","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.biopha.2026.119824_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125470","article-title":"Hurdles to healing: Overcoming cellular barriers for viral and nonviral gene therapy","volume":"674","author":"Honrath","year":"2025","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.biopha.2026.119824_bib88","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"1","key":"10.1016\/j.biopha.2026.119824_bib89","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2026.119824_bib90","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3389\/fimmu.2013.00341","article-title":"Humoral Immune Response to AAV","volume":"4","author":"Calcedo","year":"2013","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119824_bib91","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrg2988","article-title":"Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges","volume":"12","author":"Mingozzi","year":"2011","journal-title":"Nat. Rev. Genet."},{"issue":"1","key":"10.1016\/j.biopha.2026.119824_bib92","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCRESAHA.120.316363","article-title":"Molecular Basis of Atrial Fibrillation Pathophysiology and Therapy: A Translational Perspective","volume":"127","author":"Nattel","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.biopha.2026.119824_bib93","first-page":"2025","article-title":"Ion channels and atrial fibrillation: mitophagy as a key mediator","volume":"16","author":"X, Yan","year":"2025","journal-title":"Front. Physiol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119824_bib94","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1152\/physrev.00002.2005","article-title":"Molecular physiology of cardiac repolarization","volume":"85","author":"Nerbonne","year":"2005","journal-title":"Physiol. Rev."},{"issue":"9","key":"10.1016\/j.biopha.2026.119824_bib95","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.119.007465","article-title":"Genetic Ablation of TASK-1 (Tandem of P Domains in a Weak Inward Rectifying K+ Channel-Related Acid-Sensitive K+ Channel-1) (K2P3.1) K+ Channels Suppresses Atrial Fibrillation and Prevents Electrical Remodeling","volume":"12","author":"Schmidt","year":"2019","journal-title":"Circ. Arrhythm. Electrophysiol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119824_bib96","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/wmts.102","article-title":"L-type Ca2+ channels in heart and brain","volume":"3","author":"Striessnig","year":"2014","journal-title":"Wiley Interdiscip. Rev. Membr. Transp. Signal."},{"issue":"9","key":"10.1016\/j.biopha.2026.119824_bib97","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s41419-018-0860-y","article-title":"Autophagy exacerbates electrical remodeling in atrial fibrillation by ubiquitin-dependent degradation of L-type calcium channel","volume":"9","author":"Yuan","year":"2018","journal-title":"Cell. Death Dis."},{"issue":"11","key":"10.1016\/j.biopha.2026.119824_bib98","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1172\/JCI124231","article-title":"Atrial fibrillation risk loci interact to modulate Ca2+-dependent atrial rhythm homeostasis","volume":"129","author":"Laforest","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.biopha.2026.119824_bib99","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.008155","article-title":"Gene Transfer of Engineered Calmodulin Alleviates Ventricular Arrhythmias in a Calsequestrin-Associated Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia","volume":"7","author":"Liu","year":"2018","journal-title":"J. Am. Heart Assoc."},{"issue":"7","key":"10.1016\/j.biopha.2026.119824_bib100","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.hrthm.2019.01.013","article-title":"Calcium\/calmodulin-dependent protein kinase II causes atrial structural remodeling associated with atrial fibrillation and heart failure","volume":"16","author":"Liu","year":"2019","journal-title":"Heart Rhythm."},{"issue":"1","key":"10.1016\/j.biopha.2026.119824_bib101","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s44325-024-00035-5","article-title":"Genetic and molecular underpinnings of atrial fibrillation","volume":"1","author":"Sweat","year":"2024","journal-title":"npj Cardiovasc. Health"},{"issue":"3","key":"10.1016\/j.biopha.2026.119824_bib102","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/pace.14944","article-title":"Ion channel dysfunction and fibrosis in atrial fibrillation: Two sides of the same coin","volume":"47","author":"Arabia","year":"2024","journal-title":"Pacing Clin. Electrophysiol."},{"issue":"18","key":"10.1016\/j.biopha.2026.119824_bib103","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.3390\/ijms20184374","article-title":"CaMKII Activity in the Inflammatory Response of Cardiac Diseases","volume":"20","author":"Rusciano","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.biopha.2026.119824_bib104","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1097\/MS9.0000000000003499","article-title":"Inflammatory cytokines and cardiac arrhythmias: from pathogenesis to potential therapies","volume":"87","author":"Obeagu","year":"2025","journal-title":"Ann. Med. Surg. (Lond. )"},{"issue":"13","key":"10.1016\/j.biopha.2026.119824_bib105","doi-asserted-by":"crossref","first-page":"5954","DOI":"10.3390\/ijms26135954","article-title":"Inflammasome Signaling in Cardiac Arrhythmias: Linking Inflammation, Fibrosis, and Electrical Remodeling","volume":"26","author":"Karakasis","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2026.119824_bib106","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41569-022-00759-w","article-title":"Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology","volume":"20","author":"Dobrev","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119824_bib107","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/cvr\/cvad175","article-title":"An inflammation resolution-promoting intervention prevents atrial fibrillation caused by left ventricular dysfunction","volume":"120","author":"Hiram","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.biopha.2026.119824_bib108","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1273524","article-title":"The relationship between atrial fibrillation and NLRP3 inflammasome: a gut microbiota perspective","volume":"14","author":"Xing","year":"2023","journal-title":"Front. Immunol."},{"issue":"20","key":"10.1016\/j.biopha.2026.119824_bib109","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1161\/CIRCULATIONAHA.118.035202","article-title":"Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation","volume":"138","author":"Yao","year":"2018","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.biopha.2026.119824_bib110","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1161\/CIRCULATIONAHA.118.036143","article-title":"Inflammation, Inflammasome Activation, and Atrial Fibrillation","volume":"138","author":"Van Wagoner","year":"2018","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.biopha.2026.119824_bib111","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70660","article-title":"The NLRP3 Inflammasome: Mechanisms of Activation, Regulation, and Therapeutic Opportunities","volume":"7","author":"Zou","year":"2026","journal-title":"MedComm"},{"issue":"6","key":"10.1016\/j.biopha.2026.119824_bib112","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3390\/biomedicines14061362","article-title":"AMPK Signalling in Heart Failure: From Metabolic Sensor to Context-Dependent Therapeutic Target","volume":"14","author":"Arzouni","year":"2026","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.biopha.2026.119824_bib113","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1517\/14728222.2013.745513","article-title":"Caspase-3 as a therapeutic target for heart failure","volume":"17","author":"Yang","year":"2013","journal-title":"Expert. Opin. Ther. Targets"},{"key":"10.1016\/j.biopha.2026.119824_bib114","article-title":"Chen C, Chen P, Yu W, Zhao L, Yang Y, Qu H, Fu C, Shi D, Guo M. TGF-\u03b2-Driven Atrial Fibrosis in Atrial Fibrillation: From Mechanistic Insights to Targeted Therapies","year":"2025","journal-title":"Aging Dis."},{"issue":"6","key":"10.1016\/j.biopha.2026.119824_bib115","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.tcm.2014.12.015","article-title":"Atrial remodeling, fibrosis, and atrial fibrillation","volume":"25","author":"Jalife","year":"2015","journal-title":"Trends Cardiovasc. Med."},{"issue":"10","key":"10.1016\/j.biopha.2026.119824_bib116","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.3390\/antiox12101833","article-title":"NADPH Oxidases and Oxidative Stress in the Pathogenesis of Atrial Fibrillation","volume":"12","author":"Ramos-Mondrag\u00f3n","year":"2023","journal-title":"Antioxid. (Basel)"},{"issue":"18","key":"10.1016\/j.biopha.2026.119824_bib117","doi-asserted-by":"crossref","DOI":"10.1172\/JCI175447","article-title":"Modulation of NOX2 causes obesity-mediated atrial fibrillation","volume":"134","author":"Sridhar","year":"2024","journal-title":"J. Clin. Invest."},{"issue":"13","key":"10.1016\/j.biopha.2026.119824_bib118","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1161\/CIRCULATIONAHA.119.044127","article-title":"Attenuation of Oxidative Injury With Targeted Expression of NADPH Oxidase 2 Short Hairpin RNA Prevents Onset and Maintenance of Electrical Remodeling in the Canine Atrium: A Novel Gene Therapy Approach to Atrial Fibrillation","volume":"142","author":"Yoo","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2026.119824_bib119","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ahj.2023.01.010","article-title":"Evaluation of the association between circulating IL-1\u03b2 and other inflammatory cytokines and incident atrial fibrillation in a cohort of postmenopausal women","volume":"258","author":"Gomez","year":"2023","journal-title":"Am. Heart J."},{"issue":"3","key":"10.1016\/j.biopha.2026.119824_bib120","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s44161-025-00610-8","article-title":"IL-1\u03b2 enhances susceptibility to atrial fibrillation in mice by acting through resident macrophages and promoting caspase-1 expression","volume":"4","author":"Moreno-Loaiza","year":"2025","journal-title":"Nat. Cardiovasc. Res."},{"issue":"4","key":"10.1016\/j.biopha.2026.119824_bib121","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1248\/bpb.b18-00363","article-title":"IL-1\u03b2 Plays an Important Role in Pressure Overload-Induced Atrial Fibrillation in Mice","volume":"42","author":"Matsushita","year":"2019","journal-title":"Biol. Pharm. Bull."},{"issue":"12","key":"10.1016\/j.biopha.2026.119824_bib122","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/europace\/euq321","article-title":"Interleukin-18 among atrial fibrillation patients in the absence of structural heart disease","volume":"12","author":"Luan","year":"2010","journal-title":"Europace"},{"issue":"1","key":"10.1016\/j.biopha.2026.119824_bib123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/joa3.12473","article-title":"Role of inflammation in atrial fibrillation: A comprehensive review of current knowledge","volume":"37","author":"Nso","year":"2020","journal-title":"J. Arrhythm."},{"issue":"1","key":"10.1016\/j.biopha.2026.119824_bib124","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/eurheartj\/ehx261","article-title":"IL-18 cleavage triggers cardiac inflammation and fibrosis upon \u03b2-adrenergic insult","volume":"39","author":"Xiao","year":"2018","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.biopha.2026.119824_bib125","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2119\/molmed.2014.00034","article-title":"Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure","volume":"20","author":"O'Brien","year":"2014","journal-title":"Mol. Med."},{"issue":"12","key":"10.1016\/j.biopha.2026.119824_bib126","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.repc.2020.07.009","article-title":"Increased serum interleukin-6 level as a predictive biomarker for atrial fibrillation: A systematic review and meta-analysis","volume":"39","author":"Zhou","year":"2020","journal-title":"Rev. Port. Cardiol. (Engl. Ed. )"},{"issue":"6","key":"10.1016\/j.biopha.2026.119824_bib127","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.ahj.2015.09.018","article-title":"Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation","volume":"170","author":"Aulin","year":"2015","journal-title":"Am. Heart J."},{"issue":"12","key":"10.1016\/j.biopha.2026.119824_bib128","doi-asserted-by":"crossref","first-page":"872","DOI":"10.5152\/AnatolJCardiol.2021.69299","article-title":"Prognostic value of interleukin-6 in atrial fibrillation: A cohort study and meta-analysis","volume":"25","author":"Jia","year":"2021","journal-title":"Anatol. J. Cardiol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119824_bib129","first-page":"4199","article-title":"Association of Interleukin-10 promotor polymorphisms with atrial fibrillation in Han Chinese","volume":"7","author":"Zheng","year":"2014","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"5","key":"10.1016\/j.biopha.2026.119824_bib130","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.117.006040","article-title":"Interleukin 10 Treatment Ameliorates High-Fat Diet-Induced Inflammatory Atrial Remodeling and Fibrillation","volume":"11","author":"Kondo","year":"2018","journal-title":"Circ. Arrhythm. Electrophysiol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119824_bib131","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3904\/kjim.2022.266","article-title":"Omega-3 fatty acids and atrial fibrillation","volume":"38","author":"Huh","year":"2023","journal-title":"Korean J. Intern. Med."},{"issue":"2","key":"10.1016\/j.biopha.2026.119824_bib132","first-page":"502","article-title":"Effect of Omega-3 Polyunsaturated Fatty Acid Supplementation in Patients with Atrial Fibrillation","volume":"5","author":"Kumar","year":"2012","journal-title":"J. Atr. Fibrillation"},{"issue":"19","key":"10.1016\/j.biopha.2026.119824_bib133","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1161\/CIRCULATIONAHA.107.704759","article-title":"Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling","volume":"116","author":"Sakabe","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2026.119824_bib134","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2024.1423228","article-title":"The differential effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors: an updated systematic review of randomized controlled trials","volume":"11","author":"Choi","year":"2024","journal-title":"Front. Nutr."},{"issue":"21","key":"10.1016\/j.biopha.2026.119824_bib135","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1016\/j.jacc.2023.08.059","article-title":"Omega 3, Atrial Fibrillation, and Cardiovascular Outcomes","volume":"82","author":"O'Keefe","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119824_bib136","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.263","article-title":"MAG-DPA curbs inflammatory biomarkers and pharmacological reactivity in cytokine-triggered hyperresponsive airway models","volume":"4","author":"Khaddaj-Mallat","year":"2016","journal-title":"Pharmacol. Res. Perspect."},{"issue":"6","key":"10.1016\/j.biopha.2026.119824_bib137","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1007\/s11033-022-07230-6","article-title":"Resolution-promoting autacoids demonstrate promising cardioprotective effects against heart diseases","volume":"49","author":"Hiram","year":"2022","journal-title":"Mol. Biol. Rep."},{"issue":"7","key":"10.1016\/j.biopha.2026.119824_bib138","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024999","article-title":"Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE-IT","volume":"11","author":"Selvaraj","year":"2022","journal-title":"J. Am. Heart Assoc."},{"issue":"7","key":"10.1016\/j.biopha.2026.119824_bib139","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/cvr\/cvaa186","article-title":"The inflammation-resolution promoting molecule resolvin-D1 prevents atrial proarrhythmic remodelling in experimental right heart disease","volume":"117","author":"Hiram","year":"2021","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119824_bib140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s43556-025-00400-5","article-title":"Pro-resolving lipid mediators in diseases: exploring the molecular basis and clinical implication","volume":"7","author":"Li","year":"2026","journal-title":"Mol. Biomed."},{"issue":"2","key":"10.1016\/j.biopha.2026.119824_bib141","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1042\/BJ20110327","article-title":"Specialized proresolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution","volume":"437","author":"Fredman","year":"2011","journal-title":"Biochem. J."},{"issue":"2","key":"10.1016\/j.biopha.2026.119824_bib142","article-title":"The Effect of Colchicine on Atrial Fibrillation: A Systematic Review and Meta-Analysis","volume":"15","author":"Kommu","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.biopha.2026.119824_bib143","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2023.1260774","article-title":"Colchicine in atrial fibrillation: are old trees in bloom?","volume":"14","author":"Zhan","year":"2023","journal-title":"Front. Physiol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119824_bib144","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s13019-022-01958-9","article-title":"A meta-analysis of colchicine in prevention of atrial fibrillation following cardiothoracic surgery or cardiac intervention","volume":"17","author":"Zhao","year":"2022","journal-title":"J. Cardiothorac. Surg."},{"key":"10.1016\/j.biopha.2026.119824_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.132068","article-title":"Efficacy and safety of colchicine for atrial fibrillation prevention: An updated meta-analysis of randomized controlled trials","volume":"406","author":"Tian","year":"2024","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119824_bib146","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.123.012387","article-title":"Colchicine to Prevent Atrial Fibrillation Recurrence After Catheter Ablation: A Randomized, Placebo-Controlled Trial","volume":"17","author":"Benz","year":"2024","journal-title":"Circ. Arrhythm. Electrophysiol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119824_bib147","doi-asserted-by":"crossref","first-page":"590","DOI":"10.4103\/0253-7613.144905","article-title":"Colchicine in prevention of atrial fibrillation following cardiac surgery: systematic review and meta-analysis","volume":"46","author":"Trivedi","year":"2014","journal-title":"Indian. J. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119824_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.132110","article-title":"Colchicine for the prevention of atrial fibrillation: Why do some studies say 'yes', and others say 'no'?","volume":"408","author":"Attia","year":"2024","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.biopha.2026.119824_bib149","article-title":"Colchicine therapy in cardiovascular medicine: A literature review","volume":"52","author":"Trube","year":"2025","journal-title":"Am. Heart J."},{"key":"10.1016\/j.biopha.2026.119824_bib150","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijcard.2022.06.028","article-title":"Low-dose colchicine and high-sensitivity C-reactive protein after myocardial infarction: A combined analysis using individual patient data from the COLCOT and LoDoCo-MI studies","volume":"363","author":"Sun","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.biopha.2026.119824_bib151","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40824-020-00190-7","article-title":"Recent advances in polymeric drug delivery systems","volume":"24","author":"Sung","year":"2020","journal-title":"Biomater. Res."},{"key":"10.1016\/j.biopha.2026.119824_bib152","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.862164","article-title":"Role of Inflammation in the Pathogenesis of Atrial Fibrillation","volume":"13","author":"Ihara","year":"2022","journal-title":"Front. Physiol."},{"key":"10.1016\/j.biopha.2026.119824_bib153","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.2147\/JIR.S390310","article-title":"The Role of NLRP3 Inflammasome Signaling on Arrhythmias in Diabetes","volume":"15","author":"Zhang","year":"2022","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.biopha.2026.119824_bib154","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2025.1692638","article-title":"Inflammatory and fibrotic signaling pathways mediated by cardiac macrophages in atrial fibrillation","volume":"12","author":"Ren","year":"2026","journal-title":"Front. Cardiovasc. Med."},{"issue":"4","key":"10.1016\/j.biopha.2026.119824_bib155","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2011.06.012","article-title":"Interleukin-1\u03b2 inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"162","author":"Ridker","year":"2011","journal-title":"Am. Heart J."},{"key":"10.1016\/j.biopha.2026.119824_bib156","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.716721","article-title":"Communication Between Cardiomyocytes and Fibroblasts During Cardiac Ischemia\/Reperfusion and Remodeling: Roles of TGF-\u03b2, CTGF, the Renin Angiotensin Axis, and Non-coding RNA Molecules","volume":"12","author":"Flores-Vergara","year":"2021","journal-title":"Front. Physiol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119824_bib157","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euae082","article-title":"Atrial cardiomyocytes contribute to the inflammatory status associated with atrial fibrillation in right heart disease","volume":"26","author":"Le Quilliec","year":"2024","journal-title":"Europace"},{"issue":"9","key":"10.1016\/j.biopha.2026.119824_bib158","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.3390\/biomedicines11092427","article-title":"Pollutants, including Organophosphorus and Organochloride Pesticides, May Increase the Risk of Cardiac Remodeling and Atrial Fibrillation: A Narrative Review","volume":"11","author":"Le Quilliec","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2026.119824_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhazmat.2024.135533","article-title":"Daily exposure to chlordecone, an organochlorine pesticide, increases cardiac fibrosis and atrial fibrillation vulnerability","volume":"478","author":"Fundere","year":"2024","journal-title":"J. Hazard. Mater."},{"issue":"4","key":"10.1016\/j.biopha.2026.119824_bib160","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3390\/antiox14040414","article-title":"Relevance of Targeting Oxidative Stress, Inflammatory, and Pro-Resolution Mechanisms in the Prevention and Management of Postoperative Atrial Fibrillation","volume":"14","author":"Attia","year":"2025","journal-title":"Antioxid. (Basel)"},{"key":"10.1016\/j.biopha.2026.119824_bib161","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2025.1578148","article-title":"Interactions between atrial fibrosis and inflammation in atrial fibrillation","volume":"12","author":"Pang","year":"2025","journal-title":"Front. Cardiovasc. Med."},{"issue":"6","key":"10.1016\/j.biopha.2026.119824_bib162","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/FJC.0000000000000313","article-title":"Oxidant and Inflammatory Mechanisms and Targeted Therapy in Atrial Fibrillation: An Update","volume":"66","author":"Gutierrez","year":"2015","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"9721","key":"10.1016\/j.biopha.2026.119824_bib163","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S0140-6736(10)60096-7","article-title":"New antiarrhythmic drugs for treatment of atrial fibrillation","volume":"375","author":"Dobrev","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.biopha.2026.119824_bib164","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCRESAHA.117.311081","article-title":"Translational Challenges in Atrial Fibrillation","volume":"122","author":"Heijman","year":"2018","journal-title":"Circ. Res."},{"issue":"10","key":"10.1016\/j.biopha.2026.119824_bib165","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/europace\/euw161","article-title":"EHRA\/HRS\/APHRS\/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication","volume":"18","author":"Goette","year":"2016","journal-title":"Europace"},{"issue":"14","key":"10.1016\/j.biopha.2026.119824_bib166","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"EAST-AFNET 4 Trial Investigators. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation","volume":"383","author":"Kirchhof","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119824_bib167","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/ijms23010006","article-title":"Atrial Fibrillation: Pathogenesis, Predisposing Factors, and Genetics","volume":"23","author":"Sagris","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119824_bib168","doi-asserted-by":"crossref","DOI":"10.1002\/clc.70021","article-title":"Atrial Fibrillation Recurrence Risk After Catheter Ablation in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis","volume":"48","author":"Rujirachun","year":"2025","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.biopha.2026.119824_bib169","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/9295326","article-title":"Tailoring the Ablative Strategy for Atrial Fibrillation: A State-of-the-Art Review","volume":"2022","author":"Palam\u00e0","year":"2022","journal-title":"Cardiol. Res. Pract."},{"key":"10.1016\/j.biopha.2026.119824_bib170","first-page":"1","article-title":"Avoiding permanent atrial fibrillation: treatment approaches to prevent disease progression","volume":"10","author":"Shukla","year":"2014","journal-title":"Vasc. Health Risk Manag."},{"issue":"4","key":"10.1016\/j.biopha.2026.119824_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00443","article-title":"Gene therapy for the leukodystrophies: From preclinical animal studies to clinical trials","volume":"21","author":"Metovic","year":"2024","journal-title":"Neurotherapeutics"},{"issue":"5","key":"10.1016\/j.biopha.2026.119824_bib172","doi-asserted-by":"crossref","first-page":"609","DOI":"10.18609\/cgti.2020.073","article-title":"Consideration of clinical translation of cardiac AAV gene therapy","volume":"6","author":"Yamada","year":"2020","journal-title":"Cell. Gene Ther. Insights"},{"issue":"18","key":"10.1016\/j.biopha.2026.119824_bib173","doi-asserted-by":"crossref","first-page":"10314","DOI":"10.3390\/ijms231810314","article-title":"Cell-Based and Selected Cell-Free Therapies for Myocardial Infarction: How Do They Compare to the Current Treatment Options?","volume":"23","author":"Cs\u00f6b\u00f6nyeiov\u00e1","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119824_bib174","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2022.102823","article-title":"Small molecule-inducible gene regulatory systems in mammalian cells: progress and design principles","volume":"78","author":"Siddiqui","year":"2022","journal-title":"Curr. Opin. Biotechnol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119824_bib175","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2174\/1566523216666160524144041","article-title":"Tet-On Systems For Doxycycline-inducible Gene Expression","volume":"16","author":"Das","year":"2016","journal-title":"Curr. Gene Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119824_bib176","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1186\/s12872-026-05878-7","article-title":"Retrospective evaluation of the relationship between catheter ablation and systemic immune-inflammation index in cardiac arrhythmias","volume":"26","author":"Dural","year":"2026","journal-title":"BMC Cardiovasc. Disord."},{"issue":"1","key":"10.1016\/j.biopha.2026.119824_bib177","first-page":"12","article-title":"Recent advances in CRISPR-based genome editing technology and its applications in cardiovascular research","volume":"10","author":"Li","year":"2023","journal-title":"Mil. Med. Res."},{"issue":"6","key":"10.1016\/j.biopha.2026.119824_bib178","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.tcm.2020.06.008","article-title":"Translating genomic insights into cardiovascular medicine: Opportunities and challenges of CRISPR-Cas9","volume":"31","author":"Zhang","year":"2021","journal-title":"Trends Cardiovasc. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119824_bib179","doi-asserted-by":"crossref","DOI":"10.1124\/pharmrev.124.001297","article-title":"Promising tools for future drug discovery and development in antiarrhythmic therapy","volume":"77","author":"Mond\u00e9jar-Parre\u00f1o","year":"2025","journal-title":"Pharmacol. Rev."},{"issue":"4","key":"10.1016\/j.biopha.2026.119824_bib180","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2024.102431","article-title":"Advancements in gene therapy approaches for atrial fibrillation: Targeted delivery, mechanistic insights and future prospects","volume":"49","author":"Khawajakhail","year":"2024","journal-title":"Curr. Probl. Cardiol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119824_bib181","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s12265-025-10716-w","article-title":"Gene Therapy for Inherited Cardiac Arrhythmias","volume":"18","author":"Turkieltaub Paredes","year":"2025","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"10.1016\/j.biopha.2026.119824_bib182","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2026.103266","article-title":"Usefulness of healthy aging models to study novel prevention strategies in the treatment of cardiac inflammation and atrial fibrillation: A narrative review","volume":"121","author":"Rose","year":"2026","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.biopha.2026.119824_bib183","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2025.1617652","article-title":"Animal and cellular models of atrial fibrillation: a review","volume":"12","author":"Wu","year":"2025","journal-title":"Front. Cardiovasc. Med."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T22:42:16Z","timestamp":1787179336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226008607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":183,"alternative-id":["S0753332226008607"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119824","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Translational consistency of gene therapy strategies targeting inflammation in atrial fibrillation\u2019s management","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119824","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119824"}}